PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development.

Abstract The objective of this study is to evaluate the incidence of non-AIDS defining malignancies (NADMs) among people living with HIV/AIDS (PLWHA) in British Columbia, focusing on clinical correlates, highly active antiretroviral therapy (HAART) use, and survival, in order to elucidate mechanisms for NADM development.
PMID
Related Publications

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Cancer incidence among HIV-positive women in British Columbia, Canada: Heightened risk of virus-related malignancies.

AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study.

Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies.

Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study.

Authors

Mayor MeshTerms
Keywords

Aids

Cancer

Epidemiology

HAART

HIV

Malignancy

Journal Title bmc cancer
Publication Year Start




PMID- 28410587
OWN - NLM
STAT- MEDLINE
DA  - 20170415
DCOM- 20170418
LR  - 20170418
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Apr 14
TI  - Overview of cancer incidence and mortality among people living with HIV/AIDS in
      British Columbia, Canada: Implications for HAART use and NADM development.
PG  - 270
LID - 10.1186/s12885-017-3229-1 [doi]
AB  - BACKGROUND: The objective of this study is to evaluate the incidence of non-AIDS 
      defining malignancies (NADMs) among people living with HIV/AIDS (PLWHA) in
      British Columbia, focusing on clinical correlates, highly active antiretroviral
      therapy (HAART) use, and survival, in order to elucidate mechanisms for NADM
      development. METHODS: A retrospective population based analysis was carried out
      for individuals with HIV/AIDS that began their treatment between 1996 and 2008.
      RESULTS: There were 145 (2.95%) NADMs and 123 (2.50%) AIDS defining malignancies 
      (ADMs) identified in 4918 PLWHA in the study population. NADMs were represented
      by a range of cancer types including, most commonly, lung cancer, followed by
      anal, breast, head/neck, prostate, liver, rectal, and renal cancers. PLWHA had a 
      SIR of 2.05 (CI:1.73, 2.41) for the development of NADMs compared to individuals 
      without an HIV/AIDS diagnosis in the general population. Independent factors
      significantly associated with a NADM were: male gender, older age, lower CD4 cell
      counts, previous NADM, absence of HAART (non-HAART versus HAART) and treatment
      during the early-HAART era (before 2000 versus after 2000). CONCLUSIONS: NADMs
      represent an important source of morbidity for PLWHA. Use of HAART with its
      associated improvement in immune-restoration, and tailored targeted cancer
      screening interventions, may be beneficial and improve outcomes in this unique
      patient population.
FAU - Chiu, Connie G
AU  - Chiu CG
AD  - Department of Surgery, St. Paul's Hospital, & University of British Columbia,
      C303 - 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
FAU - Smith, Danielle
AU  - Smith D
AD  - Faculty small o, Cyrillicf Health Sciences, Simon Fraser University, Burnaby, BC,
      Canada.
AD  - British Columbia Centre For Excellence In HIV/AIDS, Providence Health Care, St.
      Paul's Hospital, Vancouver, BC, Canada.
FAU - Salters, Kate A
AU  - Salters KA
AD  - Faculty small o, Cyrillicf Health Sciences, Simon Fraser University, Burnaby, BC,
      Canada.
AD  - British Columbia Centre For Excellence In HIV/AIDS, Providence Health Care, St.
      Paul's Hospital, Vancouver, BC, Canada.
FAU - Zhang, Wendy
AU  - Zhang W
AD  - British Columbia Centre For Excellence In HIV/AIDS, Providence Health Care, St.
      Paul's Hospital, Vancouver, BC, Canada.
FAU - Kanters, Steve
AU  - Kanters S
AD  - British Columbia Centre For Excellence In HIV/AIDS, Providence Health Care, St.
      Paul's Hospital, Vancouver, BC, Canada.
FAU - Milan, David
AU  - Milan D
AD  - British Columbia Centre For Excellence In HIV/AIDS, Providence Health Care, St.
      Paul's Hospital, Vancouver, BC, Canada.
FAU - Montaner, Julio S G
AU  - Montaner JSG
AD  - British Columbia Centre For Excellence In HIV/AIDS, Providence Health Care, St.
      Paul's Hospital, Vancouver, BC, Canada.
AD  - Faculty of Medicine, University of British Columbia, Vancouver, Canada.
FAU - Coldman, Andy
AU  - Coldman A
AD  - Population and Preventive Oncology, British Columbia Cancer Agency, Vancouver,
      BC, Canada.
FAU - Hogg, Robert S
AU  - Hogg RS
AD  - Faculty small o, Cyrillicf Health Sciences, Simon Fraser University, Burnaby, BC,
      Canada.
AD  - British Columbia Centre For Excellence In HIV/AIDS, Providence Health Care, St.
      Paul's Hospital, Vancouver, BC, Canada.
FAU - Wiseman, Sam M
AU  - Wiseman SM
AD  - Department of Surgery, St. Paul's Hospital, & University of British Columbia,
      C303 - 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
      [email protected]
LA  - eng
PT  - Journal Article
DEP - 20170414
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*drug
      therapy/*epidemiology/mortality/pathology
MH  - Adult
MH  - Age Factors
MH  - Anti-HIV Agents/administration & dosage
MH  - Antiretroviral Therapy, Highly Active/*methods
MH  - British Columbia/epidemiology
MH  - Female
MH  - HIV Infections/*drug therapy/*epidemiology/mortality/pathology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*epidemiology/mortality/virology
MH  - Retrospective Studies
MH  - Sex Factors
PMC - PMC5391557
OTO - NOTNLM
OT  - Aids
OT  - Cancer
OT  - Epidemiology
OT  - HAART
OT  - HIV
OT  - Malignancy
EDAT- 2017/04/16 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/16 06:00
PHST- 2016/03/08 [received]
PHST- 2017/03/24 [accepted]
AID - 10.1186/s12885-017-3229-1 [doi]
AID - 10.1186/s12885-017-3229-1 [pii]
PST - epublish
SO  - BMC Cancer. 2017 Apr 14;17(1):270. doi: 10.1186/s12885-017-3229-1.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>